Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)

The purpose of phase I of this clinical trial is to learn the recommended dose of the drugs loncastuximab tesirine and rituximab in participants with post-transplant lymphoproliferative disorders (PTLD). The purpose of phase II of this clinical trial is to learn if the drugs loncastuximab tesirine and rituximab are effective in participants with post-transplant lymphoproliferative disorders (PTLD).

NCT Number	NCT07573436
Lead Sponsor	University of Utah Collaborators: ADC Therapeutics S.A.
Conditions	Post-transplant Lymphoproliferative Disorder
Enrollment	23 participants
Start Date	2026-08
Primary Completion	2030-06 (estimated)
Study Completion	2031-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-06